share_log

Intelligent Bio Solutions | S-3: Registration statement for specified transactions by certain issuers

SEC announcement ·  Mar 19 03:30
Summary by Futu AI
Intelligent Bio Solutions Inc. has filed a Form S-3 with the Securities and Exchange Commission (SEC) on March 18, 2024, for a registration statement under the Securities Act of 1933. This filing includes the registration of 6,781,166 shares of common stock, which are being offered by selling stockholders. The shares include those acquired in a private placement transaction dated March 8, 2024, and additional shares issuable upon the exercise of various warrants. The company will not receive any proceeds from the sale of shares by the selling stockholders but will receive proceeds from any cash exercise of the warrants, intended for working capital and general corporate purposes. The selling stockholders may sell the shares through various methods, including ordinary brokerage transactions, block trades, or directly to...Show More
Intelligent Bio Solutions Inc. has filed a Form S-3 with the Securities and Exchange Commission (SEC) on March 18, 2024, for a registration statement under the Securities Act of 1933. This filing includes the registration of 6,781,166 shares of common stock, which are being offered by selling stockholders. The shares include those acquired in a private placement transaction dated March 8, 2024, and additional shares issuable upon the exercise of various warrants. The company will not receive any proceeds from the sale of shares by the selling stockholders but will receive proceeds from any cash exercise of the warrants, intended for working capital and general corporate purposes. The selling stockholders may sell the shares through various methods, including ordinary brokerage transactions, block trades, or directly to purchasers. The company has agreed to indemnify the selling stockholders against certain liabilities and will bear the costs of registering the shares. Intelligent Bio Solutions Inc. is a medical technology company focused on developing non-invasive, rapid testing and screening solutions, with a product portfolio that includes the Intelligent Fingerprinting Drug Screening System and the Biosensor Platform for medical diagnostics.

The information provided by Futu AI is automatically generated by third-party artificial intelligence (AI) software based on news content. It is only available to users located outside of China mainland.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.